• Oncotelic Therapeutics posted a net loss of $2.24 million for the quarter ended March 31, 2026, widening from a net loss of $364,264 a year earlier.
• Operating loss widened to $1.85 million from $101,100, as operating expenses climbed to $1.85 million from $101,100.
• General and administrative expense rose to $1.85 million from $100,803, while research and development expense increased to $795 from $297.
• Interest expense, net increased to $295,811 from $203,797; loss on change in fair value of derivative on debt widened to $90,080 from $59,367.
• Cash fell to $84,000 at March 31, 2026 from $109,000 at Dec. 31, 2025, while GMP Bio continued advancing OT-101 combination studies and planned a Hong Kong IPO in late 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncotelic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-023181), on May 14, 2026, and is solely responsible for the information contained therein.